Asked by: Lord Hunt of Kings Heath (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what assessment they have made of the impact of increasing the National Institute for Health and Care Excellence highly specialised technology cost-effectiveness threshold on patient access to rare disease medicines.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
We have reached a landmark agreement with the United States of America that secures a preferential tariff rate of 0% for all pharmaceuticals exports to the US for at least three years, and preferential terms for the United Kingdom’s medical technology exports, meaning no additional new tariffs on medical technology. This means that, unlike anywhere else in the world, life sciences companies exporting medicines from the UK to the US will face no tariffs to do so, protecting jobs and investment in the UK.
The agreement will see the National Health Service invest approximately 25% more in innovative treatments which will be achieved through an increase to the standard cost-effectiveness threshold that the National Institute for Health and Care Excellence (NICE) uses and a change to the way in which NICE values health benefits to better reflect societal preferences.
There are currently no plans to increase the cost‑effectiveness threshold for the highly specialised technologies (HST) programme. The HST programme already operates at a much higher threshold than standard NICE technology appraisals, reflecting the challenges of bringing treatments for very rare conditions to market, and NICE has been able to recommend nearly all the treatments that have been evaluated through the HST programme for NHS use.
Asked by: Lord Hunt of Kings Heath (Labour - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what their rationale is for increasing the National Institute for Health and Care Excellence (NICE) cost-effectiveness thresholds for assessing new medicines to £25–30,000 per quality-adjusted life year; and whether they plan to apply the same proportionate increases to the NICE cost-effectiveness thresholds for highly specialised technologies.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
We have reached a landmark agreement with the United States of America that secures a preferential tariff rate of 0% for all pharmaceuticals exports to the US for at least three years, and preferential terms for the United Kingdom’s medical technology exports, meaning no additional new tariffs on medical technology. This means that, unlike anywhere else in the world, life sciences companies exporting medicines from the UK to the US will face no tariffs to do so, protecting jobs and investment in the UK.
The agreement will see the National Health Service invest approximately 25% more in innovative treatments which will be achieved through an increase to the standard cost-effectiveness threshold that the National Institute for Health and Care Excellence (NICE) uses and a change to the way in which NICE values health benefits to better reflect societal preferences.
There are currently no plans to increase the cost‑effectiveness threshold for the highly specialised technologies (HST) programme. The HST programme already operates at a much higher threshold than standard NICE technology appraisals, reflecting the challenges of bringing treatments for very rare conditions to market, and NICE has been able to recommend nearly all the treatments that have been evaluated through the HST programme for NHS use.
Asked by: Will Forster (Liberal Democrat - Woking)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps the Government is taking to help raise awareness of 22q11.2 deletion syndrome.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government is committed to improving the lives of people living with rare diseases through the UK Rare Diseases Framework. One of the priorities of the Framework is improving awareness of rare diseases among healthcare professionals, including 22q11.2 deletion syndrome, also known as DiGeorge syndrome. In England, we will publish the fifth action plan updating on the progress of this priority of the UK Rare Diseases Framework in spring 2026.
NHS England supports increased awareness and understanding of DiGeorge syndrome through the NHS Genomics Education Programme which provides accessible evidence-based resources aimed at healthcare professionals, including a dedicated page on 22q deletion syndrome to support recognition, referral and appropriate use of genomic testing. Such resources are available at the following link:
https://www.genomicseducation.hee.nhs.uk/genotes/knowledge-hub/22q11-2-deletion-syndrome/
Information for families is also available at the following link:
https://www.nhs.uk/conditions/digeorge-syndrome/
Asked by: Graeme Downie (Labour - Dunfermline and Dollar)
Question to the Home Office:
To ask the Secretary of State for the Home Department, when the technical difficulties affecting Ukrainian Visa Extension scheme applications will be resolved.
Answered by Mike Tapp - Parliamentary Under-Secretary (Home Office)
UKVI is not aware of any current technical issues impacting the Ukraine Permission Extension Scheme. In rare circumstances, applications submitted to UKVI may encounter technical difficulties, which are not related to one specific area. Once identified, UKVI strives to resolve these issues as quickly as possible, however, timescales depend on each application’s individual issues.
Asked by: Jayne Kirkham (Labour (Co-op) - Truro and Falmouth)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help prevent teenagers and young adults from contracting Meningitis B.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Meningococcal disease is rare, and the incidence has declined over the last two decades following the introduction of vaccines targeting meningococcal disease including the MenACWY teenage vaccination programme.
There is no current Meningitis B (MenB) vaccination programme for teenagers and young adults.
The importance of raising awareness in parents, teenagers and other adults about the signs and symptoms of meningitis and septicaemia remains key. There are a range of resources developed by the UK Health Security Agency (UKHSA), co-branded with the National Health Service, that set out these key messages and their importance, such as the teenage guide to immunisation. The guide is available at the following link:
https://www.gov.uk/government/publications/immunisations-for-young-people
The UKHSA collaboratively produces a university vaccine communications toolkit. This is shared with the distribution lists of Universities UK and the Association of Managers of Student Services in Higher Education (AMOSSHE), and is available at the following link:
In addition, United Kingdom guidance on the public health management of meningococcal disease provides clear advice on the management of confirmed and probable cases of invasive meningococcal disease, including MenB, to minimise onward transmission and further associated cases. This guidance is available at the following link:
Asked by: John Milne (Liberal Democrat - Horsham)
Question to the Department for Environment, Food and Rural Affairs:
To ask the Secretary of State for Environment, Food and Rural Affairs, what assessment she has made of potential economic impact of the closure of small and medium-sized abattoirs on (a) farmers, (b) abattoir owners, (c) food producers and (d) consumers in the South East.
Answered by Angela Eagle - Minister of State (Department for Environment, Food and Rural Affairs)
Small and medium abattoirs play an important role in supporting regional food systems, providing routes to market for local food producers, particularly for native and rare breeds, and sustaining diversity in the meat processing sector. The closure of several smaller abattoirs in recent years has resulted in some farmers having to find alternative slaughter facilities. This has not impacted national food security or food supply for consumers including those based in the South East of England. The national abattoir network remains resilient, continuing to deliver high-quality and safe meat products.
Defra works closely with industry stakeholders including farmers, abattoir owners and food producers through the Small Abattoirs Working Group and the Small Abattoirs Task and Finish Group. These groups bring together government and industry representatives on a regular basis and provide a forum for identifying the challenges and opportunities the sector faces, and for collaborating on practical solutions.
Asked by: Lee Anderson (Reform UK - Ashfield)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent steps his Department is taking to improve research into (a) Ocular Melanoma and (b) other rare cancers.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department invests over £1.6 billion each year on research through the National Institute for Health and Care Research (NIHR) and in 2024/25 spent £141.6 million on cancer research, signalling its high priority.
One example of a recent investment into rare cancers is the NIHR’s investment of £13.7 million in December 2025 to support ground-breaking research to develop novel brain tumour treatments in the United Kingdom, with significant further funding announcements expected shortly. Research specifically on Ocular Melanoma includes a study completed in 2022 to develop AI Techniques to Predict Eye Cancer Using Big Longitudinal Data. The NIHR is committed to ensuring that all patients, including those with rare cancers, have access to cutting-edge clinical trials and innovative, lifesaving treatments, by working to fast-track clinical trials to drive global investment into life sciences, improve health outcomes, and accelerate the development of medicines and therapies of the future, including for rare cancers
The Government also supports the Rare Cancers Private Members Bill. The bill will make it easier for clinical trials on rare cancers to take place in England, by ensuring the patient population can be more easily contacted by researchers
The NIHR continues to welcome funding applications for research into less common cancers, including ocular cancer. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality.
Asked by: Lee Anderson (Reform UK - Ashfield)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve the (a) prevention (b) diagnosis and (c) treatment of Ocular Melanoma.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The forthcoming National Cancer Plan will include further details on how we will improve outcomes for patients with cancer, as well as speeding up diagnosis and treatment, ensuring patients have access to the latest treatments and technology, and ultimately driving up this country’s cancer survival rates. This will benefit all cancer patients, including ocular melanoma patients.
Early diagnosis of cancers, including ocular melanoma, is a key focus of the National Cancer Plan. We are committed to transforming diagnostic services and will support the National Health Service to increase diagnostic capacity to meet the demand for diagnostic services through investment in new capacity.
The Department is committed to ensuring that all patients, including those with rare cancers, have access to cutting-edge clinical trials and innovative, lifesaving treatments.
The Government supports Scott Arthur’s Private Members Bill on rare cancers which will make it easier for clinical trials into rare cancers, to take place in England by ensuring the patient population can be easily contacted by researchers. This will ensure that the NHS will remain at the forefront of medical innovation and is able to provide patients with the newest, most effective treatment options, and ultimately boost survival rates.
Asked by: Bobby Dean (Liberal Democrat - Carshalton and Wallington)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether she plans to increase funding for research on low‑grade gliomas and other rare brain tumours.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department invests over £1.6 billion per year in research through the National Institute for Health and Care Research (NIHR).
The NIHR is continuing to invest in brain tumour research. For example, in December 2025, the NIHR announced the pioneering Brain Tumour Research Consortium to accelerate research into new brain tumour treatments. NIHR is investing an initial £13.7 million in the consortium with significant further funding due to be awarded early in 2026. The world-leading consortium aims to transform outcomes for adults and children and their families who are living with brain tumours, ultimately reducing lives lost to cancer.
Brain tumours are one of the toughest cancers to treat. This new NIHR investment will help researchers and clinicians understand the disease better, test new treatments earlier and make trials available to more adults and children closer to home.
The consortium brings together 48 organisations from across leading universities, National Health Service trusts, and charities, along with patients, to help deliver better research, faster. It is a coordinated national effort to improve the development and evaluation of treatments for brain tumours across adult and paediatric populations.
The NIHR continues to welcome high quality funding applications for research into any aspect of human health and care, including low-grade glioma and other rare brain tumours.
Asked by: Carla Lockhart (Democratic Unionist Party - Upper Bann)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help improve the availability of clinical trials for cancer patients across the UK.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department is committed to ensuring that all patients, including those with cancer, have access to cutting-edge clinical trials and innovative, lifesaving treatments.
The Department funds research and research infrastructure through the National Institute for Health and Care Research (NIHR), which supports National Health Service patients, the public, and NHS organisations across England to participate in high-quality research, including clinical trials into cancers.
The NIHR provides an online service called 'Be Part of Research', which promotes participation in health and social care research by allowing users to search for relevant studies, including those with cancer, and register their interest.
NHS England is delivering The NHS Cancer Vaccine Launch Pad, a platform that is speeding up access to clinical trials for cancer vaccines and immunotherapies for patients who have been diagnosed with cancer.
The forthcoming National Cancer Plan will include further details on how we will improve outcomes for cancer patients across the country. It will ensure that more patients have access to the latest treatments and technology, and to clinical trials.
The Government also supports the Rare Cancers Private Members Bill. The bill will make it easier for clinical trials, on for example pancreatic cancer, to take place in England, by ensuring the patient population can be more easily contacted by researchers.